• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

蛋白质组学分析胰腺癌细胞系和原发肿瘤,鉴定仅在体外和仅在体内表达的蛋白。

Proteomic Analysis of Cell Lines and Primary Tumors in Pancreatic Cancer Identifies Proteins Expressed Only In Vitro and Only In Vivo.

机构信息

From the National Institute for Cellular Biotechnology, Dublin City University.

Department of Hepatobiliary and Liver Transplant Surgery, St. Vincent's University Hospital.

出版信息

Pancreas. 2020 Sep;49(8):1109-1116. doi: 10.1097/MPA.0000000000001633.

DOI:10.1097/MPA.0000000000001633
PMID:32833945
Abstract

OBJECTIVES

A limited repertoire of good pancreatic ductal adenocarcinoma (PDAC) models is one of the main barriers in developing effective new PDAC treatments. We aimed to characterize 6 commonly used PDAC cell lines and compare them with PDAC patient tumor samples using proteomics.

METHODS

Proteomic methods were used to generate an extensive catalog of proteins from 10 PDAC surgical specimens, 9 biopsies of adjacent normal tissue, and 6 PDAC cell lines. Protein lists were interrogated to determine what extent the proteome of the cell lines reflects the proteome of primary pancreatic tumors.

RESULTS

We identified 7973 proteins from the cell lines, 5680 proteins from the tumor tissues, and 4943 proteins from the adjacent normal tissues. We identified 324 proteins unique to the cell lines, some of which may play a role in survival of cells in culture. Conversely, a list of 63 proteins expressed only in the patient samples, whose expression is lost in culture, may place limitations on the degree to which these model systems reflect tumor biology in vivo.

CONCLUSIONS

Our work offers a catalog of proteins detected in each of the PDAC cell lines, providing a useful guide for researchers seeking model systems for PDAC functional studies.

摘要

目的

良好的胰腺导管腺癌 (PDAC) 模型数量有限,这是开发有效新 PDAC 治疗方法的主要障碍之一。我们旨在使用蛋白质组学方法对 6 种常用的 PDAC 细胞系进行特征描述,并将其与 PDAC 患者肿瘤样本进行比较。

方法

使用蛋白质组学方法从 10 个 PDAC 手术标本、9 个相邻正常组织活检和 6 个 PDAC 细胞系中生成广泛的蛋白质目录。对蛋白质列表进行查询,以确定细胞系的蛋白质组在多大程度上反映了原发性胰腺肿瘤的蛋白质组。

结果

我们从细胞系中鉴定出 7973 种蛋白质,从肿瘤组织中鉴定出 5680 种蛋白质,从相邻正常组织中鉴定出 4943 种蛋白质。我们鉴定出 324 种仅存在于细胞系中的蛋白质,其中一些可能在细胞培养中的存活中发挥作用。相反,63 种仅在患者样本中表达而在培养中丢失的蛋白质列表,可能限制了这些模型系统在多大程度上反映体内肿瘤生物学。

结论

我们的工作提供了每种 PDAC 细胞系中检测到的蛋白质目录,为寻求 PDAC 功能研究模型系统的研究人员提供了有用的指南。

相似文献

1
Proteomic Analysis of Cell Lines and Primary Tumors in Pancreatic Cancer Identifies Proteins Expressed Only In Vitro and Only In Vivo.蛋白质组学分析胰腺癌细胞系和原发肿瘤,鉴定仅在体外和仅在体内表达的蛋白。
Pancreas. 2020 Sep;49(8):1109-1116. doi: 10.1097/MPA.0000000000001633.
2
Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients.蛋白质组学分析确定基质金属蛋白酶-9、DJ-1和α-1B-糖蛋白是胰腺导管腺癌患者胰液中过表达的蛋白质。
BMC Cancer. 2008 Aug 16;8:241. doi: 10.1186/1471-2407-8-241.
3
Application of laser capture microdissection combined with two-dimensional electrophoresis for the discovery of differentially regulated proteins in pancreatic ductal adenocarcinoma.激光捕获显微切割联合二维电泳在胰腺导管腺癌差异表达蛋白发现中的应用
Proteomics. 2003 Oct;3(10):1988-2001. doi: 10.1002/pmic.200300466.
4
Targeted and explorative profiling of kallikrein proteases and global proteome biology of pancreatic ductal adenocarcinoma, chronic pancreatitis, and normal pancreas highlights disease-specific proteome remodelling.靶向和探索性分析激肽释放酶蛋白酶和胰腺导管腺癌、慢性胰腺炎和正常胰腺的整体蛋白质组生物学,突出了疾病特异性蛋白质组重塑。
Neoplasia. 2023 Feb;36:100871. doi: 10.1016/j.neo.2022.100871. Epub 2023 Jan 5.
5
Comparative proteomic analysis for the detection of biomarkers in pancreatic ductal adenocarcinomas.用于检测胰腺导管腺癌生物标志物的比较蛋白质组学分析。
J Clin Pathol. 2008 Jan;61(1):49-58. doi: 10.1136/jcp.2006.044735. Epub 2007 Apr 5.
6
Proteomic Analysis of Malignant Ascites From Patients With Pancreatic Ductal Adenocarcinoma.胰腺导管腺癌患者恶性腹水的蛋白质组学分析。
Anticancer Res. 2021 Jun;41(6):2895-2900. doi: 10.21873/anticanres.15071.
7
Analysis of the human pancreatic stellate cell secreted proteome.人类胰腺星状细胞分泌蛋白组分析。
Pancreas. 2011 May;40(4):557-66. doi: 10.1097/MPA.0b013e318214efaf.
8
Recent advances in proteomic profiling of pancreatic ductal adenocarcinoma and the road ahead.胰腺导管腺癌的蛋白质组学分析的最新进展和未来方向。
Expert Rev Proteomics. 2017 Nov;14(11):963-971. doi: 10.1080/14789450.2017.1382356. Epub 2017 Oct 4.
9
Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.埃兹蛋白过表达预示胰腺导管腺癌预后不良。
Exp Mol Pathol. 2015 Feb;98(1):1-6. doi: 10.1016/j.yexmp.2014.11.003. Epub 2014 Nov 5.
10
Proteomic analyses of ECM during pancreatic ductal adenocarcinoma progression reveal different contributions by tumor and stromal cells.蛋白质组学分析胰腺癌进展过程中的 ECM 揭示了肿瘤细胞和基质细胞的不同贡献。
Proc Natl Acad Sci U S A. 2019 Sep 24;116(39):19609-19618. doi: 10.1073/pnas.1908626116. Epub 2019 Sep 4.

引用本文的文献

1
Clinical Proteomics: Liquid Chromatography-Mass Spectrometry (LC-MS) Purification Systems.临床蛋白质组学:液相色谱-质谱联用(LC-MS)纯化系统。
Methods Mol Biol. 2023;2699:255-269. doi: 10.1007/978-1-0716-3362-5_14.
2
Proteomics-Driven Biomarkers in Pancreatic Cancer.蛋白质组学驱动的胰腺癌生物标志物
Proteomes. 2023 Aug 7;11(3):24. doi: 10.3390/proteomes11030024.
3
Alteration in Levels of Specific miRNAs and Their Potential Protein Targets between Human Pancreatic Cancer Samples, Adjacent Normal Tissue, and Xenografts Derived from These Tumors.
人胰腺癌样本、相邻正常组织以及源自这些肿瘤的异种移植瘤之间特定微小RNA(miRNA)水平及其潜在蛋白质靶点的变化。
Life (Basel). 2023 Feb 22;13(3):608. doi: 10.3390/life13030608.
4
Neoplastic cell enrichment of tumor tissues using coring and laser microdissection for proteomic and genomic analyses of pancreatic ductal adenocarcinoma.采用钻取和激光显微切割技术对肿瘤组织进行肿瘤细胞富集,用于胰腺导管腺癌的蛋白质组学和基因组学分析。
Clin Proteomics. 2022 Oct 20;19(1):36. doi: 10.1186/s12014-022-09373-x.
5
Quantitative proteomics characterization of cancer biomarkers and treatment.癌症生物标志物与治疗的定量蛋白质组学特征分析
Mol Ther Oncolytics. 2021 Apr 20;21:255-263. doi: 10.1016/j.omto.2021.04.006. eCollection 2021 Jun 25.